Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD

Pulmonary Pharmacology and Therapeutics

Volumn 26, Issue 2, 2013, Pages 256-264

  Kempsford, Rodger ^a   Norris, Virginia ^a   Siederer, Sarah ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

2 agonist; Asthma; COPD; Pharmacodynamics; Pharmacokinetics; Vilanterol

Indexed keywords

GLUCOSE; POTASSIUM; VILANTEROL TRIFENATATE;

ABDOMINAL PAIN; ADULT; AGED; APPLICATION SITE RASH; AREA UNDER THE CURVE; ARTICLE; ASTHMA; BLURRED VISION; BODY MASS; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONSTIPATION; COUGHING; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; DYSPEPSIA; ECZEMA; EPISTAXIS; FEMALE; FORCED EXPIRATORY VOLUME; HEART PALPITATION; HEART RATE; HEART VENTRICLE EXTRASYSTOLE; HOLTER MONITORING; HOT FLUSH; HUMAN; INFLUENZA; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MODERATE PERSISTENT ASTHMA; MULTICENTER STUDY (TOPIC); MUSCULOSKELETAL PAIN; NAUSEA; NOSE OBSTRUCTION; OTALGIA; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; POWDER INHALER; PRIORITY JOURNAL; RHINOPHARYNGITIS; RHINORRHEA; SIDE EFFECT; SINGLE DRUG DOSE; SPIROMETRY; STOMATITIS; THORAX PAIN; THROAT IRRITATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREMOR; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VITAL SIGN; VOMITING;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; AGED; ASTHMA; BENZYL ALCOHOLS; BLOOD GLUCOSE; BRONCHODILATOR AGENTS; CHLOROBENZENES; ELECTROCARDIOGRAPHY; FEMALE; FORCED EXPIRATORY VOLUME; HEART RATE; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84874563028     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2012.12.001     Document Type: Article

References (17)

1. Global Initiative for Asthma (GINA), National Heart Lung and Blood Institute, National Institutes of Health. GINA report. Global strategy for asthma management and prevention. Bethesda: National Institutes of Health; 2006.
2. Global Initiative for Obstructive Lung Disease (GOLD), National Heart Lung and Blood Institute, National Institutes of Health. GOLD report. Global strategy for diagnosis, management and prevention of COPD. Bethesda: National Institutes of Health; 2009.
3. Jones P.W., Barnes N., Vogelmeier C., Lawrence D., Kramer B. Efficacy of indacaterol in the treatment of patients with COPD. Prim Care Respir J 2011, 20:380-388.
4. Slack R., Barrett V., Ford A., Knowles K. In vitro pharmacological characterisation of the β2-adrenoceptor binding kinetics of [3H]vilanterol, a novel long acting β2-agonist. Br J Pharmacol 2011, 9(3):P008.
5. 2-agonist (LABA) with rapid onset and long duration, on isolated large and small human airways. Am J Respir Crit Care Med 2010, 181:A4453.
6. Barrett V., Emmons A., Ford A., Knowles R. In vitro pharmacological characterization of GW64244, a novel long-acting β2-agonist (LABA) using human recombinant β1/2/3 adrenoceptor cAMP assays. Am J Respir Crit Care Med 2010, 181:A4451.
7. Harrell A., Siederer S., Bal J., Kempsford R. Vilanterol, a novel inhaled long-acting β2 adrenoceptor agonist (LABA), demonstrates extensive first pass clearance to metabolites with negligible pharmacological activity in man. Eur Respir J 2011, 38(Suppl. 55):137s.
8. Ford A., Hughes S., Smith C., Somers G., Ranshaw L. The therapeutic index (TI) of vilanterol trifenatate. Eur Respir J 2010, 36(Suppl. 54):208s.
9. Prime D., De Backer W., Hamilton M., Cahn A., Preece A., Kelleher D., et al. Comparison of inhalation profiles through a novel dry powder inhaler (nDPI) and lung function measurements for healthy subjects, asthma and chronic obstructive pulmonary disease (COPD) patients. Am J Respir Crit Care Med 2012, 185.
10. Celli B.R., MacNee W. ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004, 23:932-946.
11. Miller M.R., Hankinson J., Brusasco V., Burgos F., Casaburi R., Coates A., et al. Standardisation of spirometry. Eur Respir J 2005, 26(2):319-338.
12. van den Berge M., Luijk B., Bareille P., Dallow N., Postma D.S., Lammers J.-W.J. Prolonged protection of the new inhaled corticosteroid fluticasone furoate against AMP hyperresponsiveness in patients with asthma. Allergy 2010, 65(12):1531-1535.
13. Lötvall J., Bateman E.D., Bleecker E.R., Busse W., Woodcock A., Follows R., et al. Dose-related efficacy of vilanterol trifenatate (VI), a long-acting beta2 agonist (LABA) with inherent 24-hour activity, in patients with persistent asthma. Eur Respir J 2010, 36(Suppl. 54):1013s.
14. Hanania N.A., Feldman G., Zachgo W., Shim J.J., Crim C., Sanford L., et al. Safety of vilanterol trifenatate (VI) in a COPD dose-ranging study. Chest 2012, 142:119-127.
15. Santanello N.C., Zhang J., Seidenberg B., Reiss T.F., Barber B.L. What are minimal important changes for asthma measures in a clinical trial?. Eur Respir J 1999, 14:23-27.
16. Donohue J.F. Minimal clinically important differences in COPD lung function. COPD. COPD 2005, 2:111-124.
17. Kempsford R., Allen A., Kelly K., Saggu P., Crim C. A repeat dose, double-blind, placebo-controlled, thorough Qt/Qtc study to assess the cardiac safety of fluticasone furoate (FF) and vilanterol (VI) administered, 2012 of fluticasone furoate (FF) and vilanterol (VI) administered in combination. Am J Respir Crit Care Med 2012, 185:A2841.